Marksans announces completion of US FDA Post-marketing Adverse Drug Experience inspection

Marksans Pharma Ltd has announced that the United State Food and Drug Administration (US FDA) has completed a Post-marketing Adverse Drug Experience (PAD E) inspection. The inspection closed with two observations.

The inspection was conducted at its Goa, Vema manufacturing facility from 31st July, 2023 to 4th August, 2023. The inspection included comprehensive scrutiny of practices and procedures for reporting of adverse events of Marksans' marketed products.

The company will submit corrective and preventive action plan (CAP A) to the US FDA in the stipulated time frame.

Shares of Marksans Pharma Limited was last trading in BSE at Rs. 114.95 as compared to the previous close of Rs. 116.90. The total number of shares traded during the day was 161669 in over 2648 trades.

The stock hit an intraday high of Rs. 117.65 and intraday low of 113.85. The net turnover during the day was Rs. 18671067.00.

Source : Equity Bulls

Keywords

MarksansPharma INE750C01026 USFDA PADEInspection